Two phase 2 studies of N-terminal tau–targeting antibody therapy fail to show clinical efficacy in progressive supranuclear palsy, despite evidence of target engagement.
References
Golbe, L. I. & Ohman-Strickland, P. A. Brain 130, 1552–1565 (2007).
Dam, T. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01455-x (2021).
Hoglinger, G. U. et al. Lancet Neurol. 20, 182–192 (2021).
Jadhav, S. et al. Acta Neuropathol. Commun. 7, 22 (2019).
Sopko, R. et al. Neurobiol. Dis. 146, 105120 (2020).
Yanamandra, K. et al. Ann. Clin. Transl. Neurol. 2, 278–288 (2015).
Kim, B., et al. Acta Neuropathol. https://doi.org/10.1007/s00401-021-02318-y (2021).
Jabbari, E. et al. Ann. Neurol. 84, 485–496 (2018).
Alzforum. https://www.alzforum.org/news/research-news/biogen-shelves-gosuranemab-after-negative-alzheimers-trial (2021).
Jabbari, E. et al. Lancet Neurol. 20, 107–116 (2021).
Evans, L.D. et al. Preprint at bioRxiv https://doi.org/10.1101/2020.08.11.246363 (2020).
Myeku, N. et al. Nat. Med. 22, 46–53 (2016).
Ji, C. & Sigurdsson, E.M. Drugs https://doi.org/10.1007/s40265-021-01546-6 (2021).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
E.J. was a study-site sub-investigator in the gosuranemab trial. K.E.D. is a director and scientific board member of Ceracuity.
Rights and permissions
About this article
Cite this article
Jabbari, E., Duff, K.E. Tau-targeting antibody therapies: too late, wrong epitope or wrong target?. Nat Med 27, 1341–1342 (2021). https://doi.org/10.1038/s41591-021-01465-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-021-01465-9
- Springer Nature America, Inc.
This article is cited by
-
Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson’s disease with dementia
Acta Neuropathologica (2024)
-
Tau-targeting therapies for Alzheimer disease: current status and future directions
Nature Reviews Neurology (2023)
-
Tauopathies: new perspectives and challenges
Molecular Neurodegeneration (2022)
-
Disease modification in Parkinsonism: obstacles and ways forward
Journal of Neural Transmission (2022)